306 citations
,
August 2011 in “Journal of cachexia, sarcopenia and muscle” This study found that GTx-024 significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women, suggesting potential use for muscle wasting conditions.
77 citations
,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
56 citations
,
July 2014 in “PloS one” This study found that selective androgen receptor modulators (SARMs) significantly inhibited tumor growth and metastasis-promoting factors in AR-positive triple-negative breast cancer models.
19 citations
,
July 2019 in “Journal of Endocrinology” This study found that GTx-024 and Danazol had similar effects to dihydrotestosterone on uterine tissue in mice, while GTx-007 showed minimal impact on the parameters tested.
59 citations
,
April 2016 in “Breast Cancer Research and Treatment” This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.